Meeting
2018 ASCO Annual Meeting
Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.
Authors
Stefania Maraka
Neuro-Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX
Stefania Maraka , Morris D. Groves , Aaron Gerald Mammoser , Charles A. Conrad , Ivo Tremont-Lukats , Monica Elena Loghin , Barbara Jane O'Brien , Vinay K. Puduvalli , Erik P. Sulman , Kenneth R. Hess , Kenneth D. Aldape , Mark R. Gilbert , John Frederick De Groot , W. K. Alfred Yung , Marta Penas-Prado , Isaac Melguizo-Gavilanes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2044)
DOI
10.1200/JCO.2018.36.15_suppl.2044
Abstract #
2044
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran
Poster
2023 ASCO Annual Meeting
Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).
First Author: Matthias Holdhoff
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu